The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.
 
Binghe Xu
No Relationships to Disclose
 
Yongmei Yin
No Relationships to Disclose
 
Ying Fan
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Lihua Song
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Man Li
No Relationships to Disclose
 
Xi Yan
No Relationships to Disclose
 
Shusen Wang
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Pfizer
 
Tao Sun
No Relationships to Disclose
 
Yuee Teng
No Relationships to Disclose
 
Xianjun Tang
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Zhengkui Sun
No Relationships to Disclose
 
Xiaoping Jin
No Relationships to Disclose
 
Yina Diao
No Relationships to Disclose
 
Gesha Liu
No Relationships to Disclose
 
Junyou Ge
No Relationships to Disclose